" class="no-js "lang="en-US"> Celanese Announces Agreement with Johns Hopkins University
Saturday, April 20, 2024

Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Space

Celanese Corporation, a global specialty materials and chemical company, today announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye.

Direct administration of therapeutics to the suprachoroidal space is growing more common as an approach for the treatment of retinal disorders. Treatment currently consists of frequent ocular injections performed at the physician’s office. A bioinert implant based on the VitalDose® platform can provide sustained ocular drug delivery for greater than six months, providing an alternative approach for reliable, continuous dosing and reducing the treatment burden for the patient. The VitalDose® Drug Delivery Platform independently has proven biocompatibility and achieves greater than six months release of mAbs, peptides, small molecules and RNAi therapeutics, making it suitable for delivering a variety of therapeutics used for ophthalmologic conditions.

“Our collaboration with John Hopkins Department of Ophthalmology allows us to seek out scientific advancements with potential to improve patient health in ophthalmology,” said Cyonna Holmes, global business strategy leader for ophthalmology at Celanese. “The VitalDose® technology platform has potential well beyond its present commercialized applications. That’s why we explore collaborations that cross traditional boundaries with the goal to realize improvements in patient compliance and health through innovative treatments in areas like ophthalmology, women’s health, rare diseases and the central nervous system.”

Scientists at the Celanese Development & Feasibility Lab will independently conduct portions of the planned research in this dedicated pharmaceutical facility. Since opening in 2021, the lab has provided customized support to accelerate customers’ long-acting drug delivery development programs. Services include material characterization; injection molding, hot-melt extrusion and other prototyping capabilities; monolithic or multi-layer drug-loaded prototypes; in vitro characterization and drug release studies; and tooling design and development.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more